🎉 M&A multiples are live!
Check it out!

Larimar Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Larimar Therapeutics and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Larimar Therapeutics Overview

About Larimar Therapeutics

Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.


Founded

2005

HQ

United States of America
Employees

65

Website

larimartx.com

Financials

LTM Revenue n/a

LTM EBITDA -$93.1M

EV

-$58.6M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Larimar Therapeutics Financials

Larimar Therapeutics has a last 12-month revenue of n/a and a last 12-month EBITDA of -$93.1M.

In the most recent fiscal year, Larimar Therapeutics achieved revenue of n/a and an EBITDA of -$90.6M.

Larimar Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Larimar Therapeutics valuation multiples based on analyst estimates

Larimar Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$41.4M -$90.6M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$35.4M -$36.9M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Larimar Therapeutics Stock Performance

As of April 15, 2025, Larimar Therapeutics's stock price is $2.

Larimar Therapeutics has current market cap of $120M, and EV of -$58.6M.

See Larimar Therapeutics trading valuation data

Larimar Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$58.6M $120M XXX XXX XXX XXX $-1.47

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Larimar Therapeutics Valuation Multiples

As of April 15, 2025, Larimar Therapeutics has market cap of $120M and EV of -$58.6M.

Larimar Therapeutics's trades at n/a LTM EV/Revenue multiple, and 0.6x LTM EBITDA.

Analysts estimate Larimar Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Larimar Therapeutics and 10K+ public comps

Larimar Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$58.6M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA 0.6x XXX XXX XXX
P/E -1.5x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 0.8x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Larimar Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Larimar Therapeutics Valuation Multiples

Larimar Therapeutics's NTM/LTM revenue growth is Infinity%

Larimar Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.4M for the same period.

Over next 12 months, Larimar Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Larimar Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Larimar Therapeutics and other 10K+ public comps

Larimar Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth 119% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $1.4M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Larimar Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Larimar Therapeutics M&A and Investment Activity

Larimar Therapeutics acquired  XXX companies to date.

Last acquisition by Larimar Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Larimar Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Larimar Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Larimar Therapeutics

When was Larimar Therapeutics founded? Larimar Therapeutics was founded in 2005.
Where is Larimar Therapeutics headquartered? Larimar Therapeutics is headquartered in United States of America.
How many employees does Larimar Therapeutics have? As of today, Larimar Therapeutics has 65 employees.
Who is the CEO of Larimar Therapeutics? Larimar Therapeutics's CEO is Dr. Carole Ben-Maimon, M.D..
Is Larimar Therapeutics publicy listed? Yes, Larimar Therapeutics is a public company listed on NAS.
What is the stock symbol of Larimar Therapeutics? Larimar Therapeutics trades under LRMR ticker.
When did Larimar Therapeutics go public? Larimar Therapeutics went public in 2020.
Who are competitors of Larimar Therapeutics? Similar companies to Larimar Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Larimar Therapeutics? Larimar Therapeutics's current market cap is $120M
What is the current EBITDA of Larimar Therapeutics? Larimar Therapeutics's last 12-month EBITDA is -$93.1M.
What is the current EV/EBITDA multiple of Larimar Therapeutics? Current EBITDA multiple of Larimar Therapeutics is 0.6x.
Is Larimar Therapeutics profitable? Yes, Larimar Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.